You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

980 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sep 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    regorafenib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC) according to clinical criteria
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Sep 2019
Regimen
Intent: Palliative
Oct 2023
Regimen
Regimen

Pages